UCB-DERIVED CD19-SPECIFIC T CELLS FOR UNIVERSAL TREATMENT OF B-CELL MALIGNANCY


Year of Award:
2007
Award Type:
R21
Project Number:
CA116127
RFA Number:
RFA-CA-07-002
Technology Track:
Molecular & Cellular Analysis Technologies
PI/Project Leader:
COOPER, LAURENCE J.N.
Other PI or Project Leader:
N/A
Institution:
UT MD ANDERSON CANCER CTR
Currently, there are no effective treatments for disease recurrence following allogeneic hematopoietic stem- cell transplant (HSCT). T-cell therapy can target malignancies using mechanisms independent of chemo- radiotherapy, with non-overlapping and gener